Arcadia Biosciences Files Notice of Appeal to the Federal Circuit and a Lawsuit in Federal Court in New York Challenging Arista Patents on High-Fiber Resistant Starch Wheat
Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural food ingredient company, today announced that it has filed a notice of appeal to the United States Court of Appeal for the Federal Circuit (Federal Circuit) and a lawsuit in the United States District Court for the Southern District of New York (SDNY) against Arista Cereal Ingredients, Pty. Ltd. and two of its affiliates. The actions are related to Arcadia’s high-fiber Resistant Starch (RS) wheat.
“We respect the intellectual property of others and vigorously defend our own,” said Raj Ketkar, president and CEO of Arcadia. “The global wheat market is enormous – between 20 and 25 percent of people’s calories come from wheat. While we seek to assert our rights to the patents in question, there are large geographies unaffected by these patents where we continue to advance our commercialization plans for RS GoodWheat, as well as our other GoodWheat branded portfolio ingredients.”
The company’s GoodWheat branded ingredient portfolio also includes wheat varieties that deliver high levels of protein, high levels of amino acids, and lower levels of gluten, as well as better-tasting whole wheat. The company is currently harvesting sample and seed-stock crops of these varieties and expects to announce technology results and commercial launch updates following nutrition analysis studies.
“The global wheat flour market is estimated to reach approximately $200 billion by 2022. It’s a market that has seen little innovation over the past 75 years and that we believe holds tremendous opportunity for many players. We developed our GoodWheat portfolio of branded ingredients to give consumers additional wheat product choices that complement a healthy lifestyle,” said Ketkar. “We’re working to make wheat cool again.”
The Federal Circuit notice of appeal challenges the recent decision by the Patent Trial and Appeal Board (PTAB) on Arcadia’s RS GoodWheat technology, adopting a claim construction that resulted in dismissal of Arcadia’s interference action pertaining to Arista’s U.S. Patent No. 9,357,722. Arcadia believes that the PTAB’s claim construction was incorrect because it failed to follow applicable standards and adopted a claim construction inconsistent with Arista’s own statements on the scope of that patent.
The United States District Court for the Southern District of New York suit against Arista and its affiliates Vilmorin and Limagrain seeks correction of inventorship on key Arista patents and other remedies. The lawsuit asserts claims against those defendants arising out of breaches of a confidentiality agreement with Arcadia and claims that Arcadia scientists should be added as sole or joint inventors on the challenged patents. The lawsuit also asserts claims against Vilmorin, Limagrain and Arista for damages under numerous legal theories including breach of contract, unfair competition, unjust enrichment, and tortious interference.
Arcadia’s RS wheat, the result of more than a decade of development leading up to its recent commercial launch, is part of the company’s robust GoodWheat™ portfolio of branded ingredients. The company recently reported the technology achievement of an industry-leading 94 percent amylose level in its High-Fiber RS GoodWheat bread and durum (pasta) varieties without the 15-20 percent yield penalty seen in research varieties of resistant starch wheat in development by other organizations. High levels of amylose are directly correlated to levels of resistant starch and fiber in wheat. Arcadia’s RS GoodWheat, currently in test formulation studies with several consumer packaged goods companies, qualifies for the U.S. Food And Drug Administration’s labeling designation of “High in Fiber” or “A Good Source of Fiber.”
About Arcadia Biosciences, Inc.
Arcadia Biosciences, Inc. (Nasdaq: RKDA) develops and markets high-value food ingredients and nutritional oils that help meet consumer demand for a healthier diet. Arcadia’s GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. The company’s agricultural traits are being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment. For more information, visit www.arcadiabio.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: Arcadia’s and its partners’ and affiliates’ ability to develop commercial products incorporating their traits, and complete the regulatory review process for such products; Arcadia’s compliance with laws and regulations that impact Arcadia’s business, and changes to such laws and regulations; Arcadia’s future capital requirements and ability to satisfy its capital needs; Arcadia’s ability to develop, enforce and defend its intellectual property rights; and the other risks set forth in Arcadia’s filings with the Securities and Exchange Commission from time to time, including the risks set forth in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2017 and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.
Jeff Bergau, +1-312-217-0419
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
First Engineering Faculty in Canada Named after a Woman: Business Leader Gina Cody Makes Historic $15 Million Donation to Montreal’s Concordia University24.9.2018 18:15 | Tiedote
Three decades after becoming the first woman to earn a PhD in building engineering from Concordia University, Gina Parvaneh Cody, MEng 81, PhD 89, has made history by giving $15 million to her alma mater. In recognition of her transformative gift to the “Campaign for Concordia: Next-Gen. Now”, the university has named its faculty of engineering and computer science after the alumna. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005425/en/ (Photo: Business Wire) The Gina Cody School of Engineering and Computer Science is the first engineering faculty in Canada — and one of the first internationally — to be named after a woman. Gina Cody, a top business leader and building engineer, credits much of her success to Concordia because the university provided her with an entrance scholarship. “I arrived in Canada as a young student from Iran in 1979 with $2,000,” she says. “Concordia welcomed me and provided me with support
Dole’s Standard Fruit Celebrates 20-Year Milestone as Environmental Leader24.9.2018 18:00 | Tiedote
Earlier in September Dole Food Company participated in a celebration of the twentieth anniversary of the company’s initial receipt of its ISO 14001 Certification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005079/en/ Dole Fresh Fruit President Renato Acuña speaks at the anniversary celebration of Dole's landmark environmental sustainability certification. (Photo: Business Wire) On July 2, 1998, Standard Fruit Company of Costa Rica S.A., a subsidiary of Dole Food Company, Inc., became the first agricultural and banana company in the world to receive the globally recognized ISO 14001 Certification for its environmental management policy and the establishment of its Integrated Management System. With the certification, the company further strengthened its robust Environmental Management System, with results that place it at the forefront in the sustainable production of bananas and pineapples. The celebration event, h
Helsinki Joins New York in Commitment to Review Local Progress Toward Global Sustainable Development Goals24.9.2018 17:42 | Tiedote
In July 2018, the City of New York became the first city in the world to submit to the United Nations its progress toward the Sustainable Development Goals (SDG’s) on city level. As the first European city Helsinki will follow New York City and become the second city in the world in effort to showcase crucial role of cities in achieving UN agenda for people, prosperity and planet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005633/en/ As the first European city Helsinki will follow New York City and become the second city in the world in effort to showcase crucial role of cities in achieving UN agenda for people, prosperity and planet. Photo: Jussi Hellsten The Mayor of Helsinki Jan Vapaavuori announced Helsinki’s commitment to the voluntary local review at a panel conversation with New York City’s Commissioner of International Affairs Penny Abeywardena at the Social Good Summit in New York City on Sunday. Even thou
ARTMS’ QUANTM Irradiation System™ to Be Featured at Two International Conferences in September24.9.2018 16:00 | Tiedote
ARTMS Products, Inc. announced today that it has been invited to present at the National Nuclear Security Administration’s 2018 Mo-99 Topical Meeting on Tuesday, September 25th and the Third International Symposium on Technetium and other Radiometals in Chemistry and Medicine on Thursday, September 27th. Joel Kumlin will present at the 2018 Mo-99 Topical Meeting in Knoxville, TN, during Session 7, Production Projects and Technologies II, at 13:00EDT on September 25th. Mr. Kumlin will be discussing progress on implementation of the ARTMS QUANTM Irradiation System™ for producing technetium-99m. The QIS™ combines local production control and a cost-effective, easy-to-use solid target system for the production of Tc-99m on most cyclotron systems. ARTMS recently announced that the QIS™ received CE mark approval and has been installed in a number of countries throughout the world. ARTMS also announced that Dr. Paul Schaffer, CTO, has been invited to present at the Third International Symposi
Mavenir Wins 5G Asia “Best RAN Product” Award24.9.2018 16:00 | Tiedote
Mavenir, focused on transforming mobile network economics for Communications Service Providers (CSPs), is proud to be awarded 5G Asia’s 2018 ‘Best RAN Product’ award for its innovative, flexible Cloud RAN solution. Mavenir’s Cloud RAN can save operators 37% in total cost of ownership (TCO) over a five-year period due to a 49% reduction in capex and a 31% annual reduction in opex1. The TechXLR8 5G Asia Awards were announced on September 19th in Singapore and celebrate excellence in the APAC’s technology and telecommunications community with the goal of showcasing the year’s greatest industry achievements. Mavenir’s Cloud RAN extends virtualization of the network to the edge and provides strategic differentiation by enabling the remote radio units (RRUs) to interwork with the virtualized cloud base band unit (vBBU) over ethernet fronthaul (FH) to the xRAN specification published early this year. Combined with network slicing support and flexibility for the vBBU to be co-located with the
Gilead Subsidiary to Launch Authorized Generics of Epclusa® (Sofosbuvir/Velpatasvir) and Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C24.9.2018 15:30 | Tiedote
Gilead Sciences, Inc. (NASDAQ: GILD) announced today plans to launch authorized generic versions of Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni® (ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. The authorized generics will launch at a list price of $24,000 for the most common course of therapy and will be available in January 2019. Since the launch of Gilead’s first HCV medication in 2013, the average price paid for each bottle of medicine in the United States has decreased by more than 60 percent off of the public list prices, across health insurers and government payers. Due to the complexity and structure of the U.S. healthcare system, however, these discounts provided by Gilead may not always translate into lower costs for patients. Further, existing contracts, together with laws associated with government pricing policies, make it cha
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme